1. Academic Validation
  2. Phenotypic rescue via mTOR inhibition in neuron-specific Pten knockout mice reveals AKT and mTORC1-site specific changes

Phenotypic rescue via mTOR inhibition in neuron-specific Pten knockout mice reveals AKT and mTORC1-site specific changes

  • Mol Psychiatry. 2025 Feb 14. doi: 10.1038/s41380-025-02916-2.
Angelica D'Amore # 1 Maria Sundberg # 1 Rui Lin # 1 Ella T Lubbers 1 Kellen D Winden 1 Lucy Yu 1 Kinga Gawlinska 1 2 Dawid Gawlinski 1 Sam G Lopez 1 Yongho Choe 1 Emma V Wightman 1 Yini Liang 1 Meera Modi 1 Christopher J Yuskaitis 1 3 Henry Hing Cheong Lee 1 4 Alexander Rotenberg 1 3 Mustafa Sahin 5 6
Affiliations

Affiliations

  • 1 Department of Neurology, FM Kirby Neurobiology Center, Boston Children's Hospital, Harvard Medical School, Boston, USA.
  • 2 Department of Clinical Pharmacy, Jagiellonian University, Medical College, Medyczna 9, PL 30-688, Krakow, Poland.
  • 3 Division of Epilepsy and Clinical Neurophysiology, Boston Children's Hospital, Boston, USA.
  • 4 Rosamund Stone Zander Translational Neuroscience Center, Boston Children's Hospital, Boston, USA.
  • 5 Department of Neurology, FM Kirby Neurobiology Center, Boston Children's Hospital, Harvard Medical School, Boston, USA. Mustafa.Sahin@childrens.harvard.edu.
  • 6 Rosamund Stone Zander Translational Neuroscience Center, Boston Children's Hospital, Boston, USA. Mustafa.Sahin@childrens.harvard.edu.
  • # Contributed equally.
Abstract

Phosphatase and Tensin Homolog (PTEN) is a dual-specific protein and lipid Phosphatase that regulates Akt and downstream signaling of the mechanistic target of rapamycin (mTOR). PTEN functions as a tumor suppressor gene whose mutations result in PTEN Hamartoma Tumor Syndrome (PHTS) characterized by increased Cancer risk and neurodevelopmental comorbidity. Here, we generated a novel neuron-specific PTEN knock-out mouse model (Syn-Cre/PTEN HOM) to test the ability of pharmacologic mTOR inhibition to rescue PTEN mutation-associated disease phenotypes in vivo and in vitro. We found that treatment with the mTOR Inhibitor, everolimus, increased the survival of Syn-Cre/PTEN HOM mice while some neurologic phenotypes persisted. Transcriptomic analyses revealed that in contrast to mice harboring a neuron-specific deletion of the Tuberous Sclerosis Complex 2 gene (Syn-Cre/Tsc2 KO), genes that are under Akt regulation were significantly increased in the Syn-Cre/PTEN HOM mice. In addition, genes associated with synapse, extracellular matrix, and myelination were broadly increased in Syn-Cre/PTEN HOM mouse neocortex. These findings were confirmed by immunostaining of cortical sections in vivo, which revealed excessive immunoreactivity of myelin basic protein and perineuronal nets (PNN), the specialized extracellular matrix surrounding fast-spiking parvalbumin (PV) interneurons. We also detected increased expression of Synapsin I/PSD95 positive synapses and network hyperactivity phenotypes in Syn-Cre/PTEN HOM mice neurons compared to wild-type (WT) neurons in vitro. Strikingly, everolimus treatment rescued the number of synapses and network hyperactivity in the Syn-Cre/PTEN HOM mice cortical neuron cultures. Taken together, our results revealed in vivo and in vitro molecular and neuronal network mechanisms underlying neurological phenotypes of PHTS. Notably, pharmacologic mTOR inhibition by everolimus led to successful downstream signaling rescue, including mTOR complex 1 (mTORC1) site-specific suppression of S6 phosphorylation, correlating with phenotypic rescue found in our novel neuron-specific Syn-Cre/PTEN HOM mice.

Figures
Products